Remdesivir, which is administered intravenously in hospital, is the first drug to show improvement in Covid-19 patients in formal clinical trials, and new information about its efficacy is being closely watched around the world, as nations battle the pandemic.
Gilead Sciences had on May 29 applied for marketing authorisation for remdesivir in India. The drug is being touted as a potential treatment for Covid-19. Gilead Sciences, the patent holder of the drug, has the complete data about the pre-clinical and clinical studies for remdesivir.
Gilead Sciences Inc has entered into non-exclusive licensing agreements with pharma firms, including three domestic majors Cipla, Jubilant Life Sciences and Hetero, for manufacture and distribution of remdesivir.
Remdesivir is being closely watched after the US Food and Drug Administration granted emergency use authorisation (EUA) last month, citing results from a US government study that showed the drug reduced hospitalisation stays by 31 per cent, or about four days, compared to a placebo.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
-
Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
-
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in